State Street SPDR S&P Biotech ETF (NY:XBI)

154.43 -0.08 (-0.05%)

Official Closing Price Updated: 8:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about State Street SPDR S&P Biotech ETF

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

16 17 Next >

Small Caps Are On A Tear Including Speculative Biotechs ↗

December 26, 2023

So far 2023 is going well with our game plan -an end-of-year seasonal rally coupled with a run in speculative biotechs driven by innovation.

Via Talk Markets

US Stocks Eye 7-Day Winning Streak As Mortgage Rates Fall Below 7%, Yields Tumble: What's Driving Markets Thursday? ↗

December 14, 2023

It’s shaping up to be a positive Thursday on Wall Street, with risk sentiment remaining robust after the Federal Reserve effectively opened the door to rate cuts in 2024.

Via Benzinga

Topics Economy

Stocks Hold Steady, Yields Decline As Fed Meeting Looms: What's Driving Markets Wednesday? ↗

December 13, 2023

Midway through the trading day on Wall Street, calm reigns supreme as investors eagerly await the Federal Reserve’s decision on interest rates.

Via Benzinga

Topics Economy

Are These Biotechs Ready To Launch? ↗

December 09, 2023

Biotech stocks are still in the process of repairing the damage from recent months — and recent years. Indeed, as of a month ago, the SPDR Biotech Fund had been dead money for an unbelievable eight and...

Via Talk Markets

Can Small Cap Biotech Stocks Continue To Run? Let’s Take A Look ↗

December 05, 2023

Over the past 4 weeks, we have seen a nice run in small-cap, speculative biotech stocks. This coincided with the pause in interest rates and expectations of the seasonal year-end rally.

Via Talk Markets

Fed Rate Cut Speculations Rattle Stocks, Commodities Slide, Bitcoin Shines: What's Driving Markets Monday? ↗

December 04, 2023

Stocks opened the first week of December with significant losses, driven by some emerging concerns of exaggerated rate cut speculations within the trading community.

Via Benzinga

Topics Economy

Stocks, Gold, Bonds Rally Further, Dollars Tumbles As Traders Anticipate Fed Cuts: What's Driving Markets Friday? ↗

December 01, 2023

Kicking off the new month, Wall Street continued its strong November momentum, with major U.S. stocks rallying on Friday.

Via Benzinga

Topics Economy

S&P 500, Nasdaq Slip As Tech Underperforms, Oil Reacts to OPEC+: What's Driving Markets Thursday? ↗

November 30, 2023

Thursday’s trading session on Wall Street presents a mixed picture, characterized by notable fluctuations in major indices. While tech-heavy benchmarks like the S&P 500 and the Nasdaq 100 are...

Via Benzinga

Topics Stocks

Stocks Drift Higher On Stronger GDP Data, Oil Rebounds As OPEC+ Mulls Cuts: What's Driving Markets Wednesday? ↗

November 29, 2023

Stocks are experiencing their 16th green session out of the 20 so far in November, with the S&P 500 index reaching its highest level since early August, and the Nasdaq 100 just 4.4% below its all-time...

Via Benzinga

US Stocks Rebound As Treasury Yields, Dollar Fall On Dovish Fed Remarks, Gold Hits $2,040: What's Driving Markets Tuesday? ↗

November 28, 2023

U.S. stocks experienced a welcome resurgence on Tuesday, buoyed by the latest comments from Federal Reserve officials.

Via Benzinga

Topics Economy

Biotech And Healthcare Portfolio Playbook For December 2023/24 ↗

November 27, 2023

We are having a great but choppy market recovery over the past four weeks and it looks like it should continue through to the next earnings cycle in January.

Via Talk Markets

Are You A Trader Or Investor: Biotech Momentum Is Picking Up ↗

November 20, 2023

ETFs have not helped as portfolio fillers but they can identify trends. We should play this rally out of a biotech bear market.

Via Talk Markets

Topics ETFs

3 Biotech Stocks That Could Boom or Bust by 2025 ↗

November 16, 2023

Biotech stocks are popular with investors because they sometimes provide tremendous rewards. Here are three to buy for a potential payday.

Via InvestorPlace

Healthcare Playbook: Hardly Defensive With A Covid Hangover In Biotech ↗

November 01, 2023

Market Bubbles may take a long time to clear and we created a big one in July 2021 dealing with the COVID pandemic.

Via Talk Markets

This Week’s Data Dump May Lead To More Stock Market Pain ↗

October 29, 2023

This week will feature data that is not only going to move the markets, but also set the tone for fourth-quarter GDP growth. This means the dollar and rates will be more volatile, and the equity market...

Via Talk Markets

It's Hard to Be a Biotech Bull in This Market, but This Stock Is a Buy ↗

October 24, 2023

The market's dour reaction to Roivant Sciences' latest deal doesn't add up.

Via The Motley Fool

Pivotal Week Coming Up: Big Tech Earnings, Geopolitics, Technicals, Treasury Yield... ↗

October 23, 2023

The upcoming quarter GDP is expected to hit 3.7% which has brought the FED dialogue to “higher rates for longer” which might lead us to a recession in 2024. So watch the yield on the 10-year TSY now at...

Via Talk Markets

Topics Economy

Thoughts For Thursday: War Worries Rattle The Market ↗

October 19, 2023

Via Talk Markets

Too Much To Handle For Stocks As Rates Continue To Rise ↗

October 18, 2023

Stocks finished sharply lower as rates reached new cycle highs on the long end of the curve, and the yield curve steepened. This led to a drop of about 1.3% on the S&P 500, bringing the index down to...

Via Talk Markets

Topics Economy Stocks

Stocks and Bonds Go Their Separate Ways ↗

October 16, 2023

Stocks were up today by around 1.1% on the S&P 500, but we have gone nowhere now in a week, so the bulls are making no progress.

Via Talk Markets

Topics Stocks

Large Cap Biopharmaceuticals-Core Holdings For Your Healthcare Portfolio Until M&A Action Picks Up ↗

October 09, 2023

Healthcare has not been a strong sector in 2023. Despite its history of being defensive in turbulent times the sector has underperformed as higher rates curb buyers sentiment.

Via Talk Markets

Stocks Rally And Rates Drop But Trends Remain In Place ↗

October 04, 2023

Stocks increased on Wednesday, rising by around 80 bps, as the dollar and rates fell. There is still a lot of data to come this week, with the Job report on Friday now front and center.

Via Talk Markets

Don’t Miss the Boom: 3 ETFs Set to Explode Higher ↗

September 27, 2023

The market may be uncertain. But these three ETFs to buy are set to deliver fantastic returns regardless of the broader economic climate.

Via InvestorPlace

Topics ETFs

Healthcare Playbook Revisited - Growth Plus Value ↗

September 13, 2023

Despite concerns about rising healthcare costs and ever more expensive technology for treatment encompassing drugs, devices, and data management, still innovative medicine marches on.

Via Talk Markets

Buy List Alert: 3 Pharma Stocks with Positive Trial Updates ↗

September 13, 2023

These three pharma stocks could be driven higher amidst future revenue prospects as they report to investors positive clinical developments.

Via InvestorPlace

EXCLUSIVE: Kidney Care Revolution? How Swedish Biopharma Calliditas Aims To Tackle A Rare Disease With 'Unique, But Pretty Simple' Drug ↗

September 08, 2023

Calliditas, a rare disease company focused on kidney ailments, is optimistic of its lead drug taking off in a big way.

Via Benzinga

Healthcare Portfolio: A Mixed Market Looking for Value ↗

September 05, 2023

Many healthcare stocks may be defensive in nature but if you are overweight the basic plays like the XLV or biotech funds like the Fidelity Biotechnology Fund you are trailing the market over the past...

Via Talk Markets

Life Science Mutual Funds Compared To ETFs And What Is In Your Portfolio? ↗

August 30, 2023

It is important to track sectors of the market because trends to create volatility. For example the COVID pandemic created a diagnostics and vaccine revenue bubble that dissipated over several months.

Via Talk Markets

Topics ETFs

If You Invested $1000 In Vivek Ramaswamy-Founded Roivant When He Declared Presidential Bid, Here's How Much You'd Have Now ↗

August 25, 2023

Roivant stock has outperformed the broader market and the biotech sector this year, mirroring the rise in the fortunes of its founder Vivek Ramaswamy.

Via Benzinga

3 Sorry Pharma Stocks to Sell in August Before It’s Too Late ↗

August 22, 2023

Factors in the marketplace caused these companies to underperform, making them some of the top pharma stocks to sell.

Via InvestorPlace

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.